DSGN vs EDSA

Design Therapeutics, Inc. vs Edesa Biotech, Inc. — Valuation Comparison 2026

DSGN

Pharmaceutical Preparations
Design Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$10.48
Last close
Models
7/13
Active
VS

EDSA

Pharmaceutical Preparations
Edesa Biotech, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$7.22
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DSGN Fair ValueDSGN Upside EDSA Fair ValueEDSA Upside
Bayesian DCF Intrinsic $3.02 -71.1% $3.47 -51.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.57 -94.6% $0.65 -91.0%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DSGN vs EDSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DSGN vs EDSA — Which Stock Is More Undervalued?

DSGN scores higher with a 4.1/10 quality rating vs EDSA's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Design Therapeutics, Inc. (DSGN) and Edesa Biotech, Inc. (EDSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DSGN currently trades at $10.48 with a QOC of 4.1/10, while EDSA trades at $7.22 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).